Stock Analysis on Net
Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Cytokinetics Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Accounts payable 2.52 2.51 1.51 2.82 1.78
Clinical and preclinical costs 1.59 1.65 1.15 0.76 4.08
Compensation related 2.15 1.77 2.21 2.88 2.90
Other accrued expenses 0.61 0.66 0.26 0.54 0.48
Accrued liabilities 4.35% 4.09% 3.62% 4.18% 7.46%
Current portion of term loan 0.00 0.00 0.00 0.00 1.23
Short-term operating lease liabilities 1.26 1.77 0.52 1.59 0.00
Short-term finance lease liabilities 0.10 0.06 0.00 0.00 0.00
Other current liabilities 0.11 0.12 0.20 0.39 0.03
Current liabilities 8.34% 8.54% 5.84% 8.98% 10.51%
Term loan, net, excluding current portion 6.29 5.63 8.66 15.55 18.85
Convertible notes, net 53.79 11.35 16.77 29.05 0.00
Liabilities related to revenue participation right purchase agreements, net 29.61 21.28 31.11 49.44 58.00
Long-term deferred revenue 0.00 10.34 16.30 0.00 0.00
Long-term operating lease liabilities 12.50 13.34 0.08 0.76 0.00
Long-term finance lease liabilities 0.10 0.10 0.00 0.00 0.00
Other non-current liabilities 0.00 0.43 0.00 0.00 0.37
Non-current liabilities 102.29% 62.47% 72.91% 94.79% 77.21%
Total liabilities 110.63% 71.01% 78.76% 103.77% 87.72%
Preferred stock, $0.001 par value; issued and outstanding: none 0.00 0.00 0.00 0.00 0.00
Common stock, $0.001 par value 0.01 0.01 0.01 0.02 0.03
Additional paid-in capital 146.00 172.62 207.09 294.44 364.01
Accumulated other comprehensive income (loss) -0.35 -0.10 0.03 0.23 0.24
Accumulated deficit -156.29 -143.54 -185.89 -298.47 -351.99
Stockholders’ equity (deficit) -10.63% 28.99% 21.24% -3.77% 12.28%
Total liabilities and stockholders’ equity (deficit) 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Cytokinetics Inc. current liabilities as a percentage of total liabilities and stockholders’ equity (deficit) increased from 2020 to 2021 but then slightly decreased from 2021 to 2022.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Cytokinetics Inc. non-current liabilities as a percentage of total liabilities and stockholders’ equity (deficit) decreased from 2020 to 2021 but then increased from 2021 to 2022 exceeding 2020 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Cytokinetics Inc. total liabilities as a percentage of total liabilities and stockholders’ equity (deficit) decreased from 2020 to 2021 but then increased from 2021 to 2022 exceeding 2020 level.
Stockholders’ equity (deficit) Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Cytokinetics Inc. stockholders’ equity (deficit) as a percentage of total liabilities and stockholders’ equity (deficit) increased from 2020 to 2021 but then decreased significantly from 2021 to 2022.